eflornithine has been researched along with Disease Exacerbation in 25 studies
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.
eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although tamoxifen appears to markedly reduce breast cancer risk in women with a prior diagnosis of atypical hyperplasia or in situ carcinoma, it is not clear what other groups of women receive substantial benefit." | 8.81 | Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. ( Fabian, CJ; Kimler, BF, 2001) |
| "Although tamoxifen appears to markedly reduce breast cancer risk in women with a prior diagnosis of atypical hyperplasia or in situ carcinoma, it is not clear what other groups of women receive substantial benefit." | 4.81 | Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. ( Fabian, CJ; Kimler, BF, 2001) |
| "Disease progression was observed in 2 of 54 (3." | 3.11 | Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial. ( Balaguer, F; Boytim, ML; Bruckheimer, EM; Burke, CA; Church, J; Cohen, A; Dekker, E; Du, W; Hüneburg, R; Lim, RM; Lynch, PM; Samadder, NJ; Stoffel, EM; Van Cutsem, E; Wise, PE, 2022) |
| "In this trial involving patients with familial adenomatous polyposis, the incidence of disease progression was not significantly lower with the combination of eflornithine and sulindac than with either drug alone." | 2.94 | Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. ( Balaguer, F; Burke, CA; Burn, J; Castells, A; Church, J; Cohen, A; Dekker, E; Ford, M; Gallinger, S; Ginsberg, GG; Grady, WM; Gryfe, R; Gupta, S; Henderson, A; Hüneburg, R; Kallenberg, FG; Kanth, P; Lalloo, F; Lim, R; Lynch, P; Roos, VH; Rustgi, AK; Samadder, NJ; Sinicrope, FA; Stoffel, EM; Strassburg, CP; Syngal, S; Van Cutsem, E; Weiss, JM; Willingham, FF; Wise, PE, 2020) |
| "The pathogenesis of Alzheimer's disease (AD) is a critical unsolved question; and although recent studies have demonstrated a strong association between altered brain immune responses and disease progression, the mechanistic cause of neuronal dysfunction and death is unknown." | 1.42 | Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. ( Brown, CM; Colton, CA; Everhart, AL; Gunn, MD; Hoofnagle, AN; Jansen, M; Kan, MJ; Lee, JE; Vitek, MP; Wilson, JG, 2015) |
| "Eflornithine seems to be a better first-line therapy for treating late-stage Gambian trypanosomiasis in the Republic of the Congo." | 1.33 | Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. ( Balasegaram, M; Checchi, F; Ghorashian, S; Hamel, C; Harris, S; Karunakara, U, 2006) |
| " However, a dose-response reduction in invasive carcinoma growth was observed for both DFMO, an inhibitor of ornithine decarboxylase, and DHEA, the primary steroid precursor to both androgens and estrogens in primates." | 1.31 | 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. ( Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burke, CA | 3 |
| Dekker, E | 3 |
| Lynch, P | 1 |
| Samadder, NJ | 3 |
| Balaguer, F | 2 |
| Hüneburg, R | 2 |
| Burn, J | 1 |
| Castells, A | 1 |
| Gallinger, S | 1 |
| Lim, R | 1 |
| Stoffel, EM | 2 |
| Gupta, S | 1 |
| Henderson, A | 1 |
| Kallenberg, FG | 1 |
| Kanth, P | 1 |
| Roos, VH | 1 |
| Ginsberg, GG | 1 |
| Sinicrope, FA | 1 |
| Strassburg, CP | 1 |
| Van Cutsem, E | 2 |
| Church, J | 2 |
| Lalloo, F | 1 |
| Willingham, FF | 1 |
| Wise, PE | 2 |
| Grady, WM | 1 |
| Ford, M | 1 |
| Weiss, JM | 1 |
| Gryfe, R | 1 |
| Rustgi, AK | 1 |
| Syngal, S | 1 |
| Cohen, A | 3 |
| Lynch, PM | 1 |
| Lim, RM | 1 |
| Boytim, ML | 1 |
| Du, W | 1 |
| Bruckheimer, EM | 1 |
| Mohammed, A | 2 |
| Janakiram, NB | 2 |
| Madka, V | 1 |
| Ritchie, RL | 1 |
| Brewer, M | 3 |
| Biddick, L | 2 |
| Patlolla, JM | 1 |
| Sadeghi, M | 1 |
| Lightfoot, S | 2 |
| Steele, VE | 2 |
| Rao, CV | 2 |
| Lozier, AM | 1 |
| Rich, ME | 1 |
| Grawe, AP | 1 |
| Peck, AS | 1 |
| Zhao, P | 1 |
| Chang, AT | 1 |
| Bond, JP | 1 |
| Sholler, GS | 1 |
| Kan, MJ | 1 |
| Lee, JE | 1 |
| Wilson, JG | 1 |
| Everhart, AL | 1 |
| Brown, CM | 1 |
| Hoofnagle, AN | 1 |
| Jansen, M | 1 |
| Vitek, MP | 1 |
| Gunn, MD | 1 |
| Colton, CA | 1 |
| Evageliou, NF | 1 |
| Haber, M | 1 |
| Vu, A | 1 |
| Laetsch, TW | 1 |
| Murray, J | 1 |
| Gamble, LD | 1 |
| Cheng, NC | 1 |
| Liu, K | 1 |
| Reese, M | 1 |
| Corrigan, KA | 1 |
| Ziegler, DS | 1 |
| Webber, H | 1 |
| Hayes, CS | 1 |
| Pawel, B | 1 |
| Marshall, GM | 1 |
| Zhao, H | 1 |
| Gilmour, SK | 1 |
| Norris, MD | 1 |
| Hogarty, MD | 1 |
| Stoffel, E | 1 |
| Bryant, T | 1 |
| Zhang, Y | 2 |
| Duff, A | 1 |
| Singh, A | 1 |
| Anderson, MW | 1 |
| Goodin, C | 1 |
| Kim, S | 1 |
| Estensen, RD | 1 |
| Wiedmann, TS | 1 |
| Sekar, P | 1 |
| Buncher, CR | 1 |
| Khoury, JC | 1 |
| Garbow, JR | 1 |
| You, M | 1 |
| Tichelaar, JW | 1 |
| Fischer, SM | 1 |
| Conti, CJ | 1 |
| Viner, J | 1 |
| Aldaz, CM | 1 |
| Lubet, RA | 1 |
| Ranger-Moore, J | 1 |
| Alberts, DS | 1 |
| Montironi, R | 1 |
| Garcia, F | 1 |
| Davis, J | 1 |
| Frank, D | 1 |
| Mariuzzi, GM | 1 |
| Bartels, HG | 1 |
| Bartels, PH | 1 |
| Balasegaram, M | 2 |
| Harris, S | 2 |
| Checchi, F | 2 |
| Hamel, C | 2 |
| Karunakara, U | 2 |
| Ghorashian, S | 1 |
| Levin, VA | 2 |
| Jochec, JL | 1 |
| Shantz, LM | 1 |
| Aldape, KD | 1 |
| Brawley, OW | 1 |
| Thompson, IM | 1 |
| Buckner, JC | 1 |
| Burch, PA | 1 |
| Cascino, TL | 1 |
| O'Fallon, JR | 1 |
| Scheithauer, BW | 1 |
| Boiko, IV | 1 |
| Mitchell, MF | 2 |
| Hu, W | 1 |
| Pandey, DK | 1 |
| Mathevet, P | 1 |
| Malpica, A | 1 |
| Hittelman, WN | 1 |
| Arbeit, JM | 1 |
| Riley, RR | 1 |
| Huey, B | 1 |
| Porter, C | 1 |
| Kelloff, G | 2 |
| Lubet, R | 2 |
| Ward, JM | 1 |
| Pinkel, D | 1 |
| Poulin, N | 1 |
| Boiko, I | 1 |
| MacAulay, C | 1 |
| Boone, C | 1 |
| Nishioka, K | 1 |
| Hittelman, W | 1 |
| Bacus, JW | 1 |
| Boone, CW | 1 |
| Bacus, JV | 1 |
| Follen, M | 1 |
| Kelloff, GJ | 1 |
| Kagan, V | 1 |
| Lippman, SM | 1 |
| Herbert, BS | 1 |
| Wright, AC | 1 |
| Passons, CM | 1 |
| Wright, WE | 1 |
| Ali, IU | 1 |
| Kopelovich, L | 1 |
| Shay, JW | 1 |
| Hess, KR | 1 |
| Wong, ET | 1 |
| Jaeckle, KA | 1 |
| Kyritsis, AP | 1 |
| Prados, MD | 1 |
| Yung, WK | 1 |
| Green, JE | 1 |
| Shibata, MA | 1 |
| Shibata, E | 1 |
| Moon, RC | 1 |
| Anver, MR | 1 |
| Fabian, CJ | 1 |
| Kimler, BF | 1 |
| Umar, A | 1 |
| Viner, JL | 1 |
| Hawk, ET | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis[NCT01483144] | Phase 3 | 171 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Improved | Not Improved | |
| Eflornithine Plus Sulindac | 22 | 34 |
| Eflornithine Plus Sulindac Placebo | 16 | 41 |
| Sulindac Plus Eflornithine Placebo | 22 | 36 |
Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint. (NCT01483144)
Timeframe: through month 12 assessment
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Improved | Not Improved | |
| Eflornithine Plus Sulindac | 11 | 45 |
| Eflornithine Plus Sulindac Placebo | 10 | 47 |
| Sulindac Plus Eflornithine Placebo | 10 | 48 |
Progression of disease by evaluation of FAP-related events over the course of study treatment (NCT01483144)
Timeframe: Up to 48 months from the start of treatment
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Number with FAP-related events | Number with Lower GI FAP-related events | |
| Eflornithine Plus Sulindac | 18 | 2 |
| Eflornithine Plus Sulindac Placebo | 23 | 10 |
| Sulindac Plus Eflornithine Placebo | 22 | 9 |
2 reviews available for eflornithine and Disease Exacerbation
| Article | Year |
|---|---|
Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention.
Topics: Aneuploidy; Angiogenesis Inhibitors; Anticarcinogenic Agents; Apoptosis; Aromatase Inhibitors; Breas | 2001 |
The future of colon cancer prevention.
Topics: Adenocarcinoma; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; | 2001 |
7 trials available for eflornithine and Disease Exacerbation
| Article | Year |
|---|---|
Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis.
Topics: Adenomatous Polyposis Coli; Adult; Disease Progression; Drug Therapy, Combination; Eflornithine; Fem | 2020 |
Combination of Sulindac and Eflornithine Delays the Need for Lower Gastrointestinal Surgery in Patients With Familial Adenomatous Polyposis: Post Hoc Analysis of a Randomized Clinical Trial.
Topics: Adenomatous Polyposis Coli; Adult; Disease Progression; Eflornithine; Humans; Proctocolectomy, Resto | 2022 |
Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2016 |
The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial.
Topics: 5-alpha Reductase Inhibitors; Androgens; Antineoplastic Agents; Chemoprevention; Combined Modality T | 1996 |
Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma.
Topics: Adult; Aged; Disease Progression; Drug Therapy, Combination; Eflornithine; Female; Glioma; Humans; I | 1998 |
Nuclear morphometry as an intermediate endpoint biomarker in chemoprevention of cervical carcinoma using alpha-difluoromethylornithine.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Nucleus; Disease Progressio | 1999 |
Response and progression in recurrent malignant glioma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Aged, 80 and over; Alitretinoin; Antineoplastic Combine | 1999 |
16 other studies available for eflornithine and Disease Exacerbation
| Article | Year |
|---|---|
Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Disease Pro | 2014 |
Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease P | 2015 |
Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antigens, CD; Arginine; Bra | 2015 |
Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cell Line | 2016 |
Potentiating NK cell activity by combination of Rosuvastatin and Difluoromethylornithine for effective chemopreventive efficacy against Colon Cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; beta Catenin; Colonic Neoplasms; Cyclin D1; Disease | 2016 |
Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice.
Topics: Aerosols; Animals; Antineoplastic Agents; Chemoprevention; Disease Progression; Eflornithine; Female | 2008 |
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; Disease Progr | 2003 |
Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Disease Progression; | 2005 |
Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
Topics: Adolescent; Adult; Animals; Child; Cohort Studies; Democratic Republic of the Congo; Disease Progres | 2006 |
Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo.
Topics: Adolescent; Adult; Animals; Child; Democratic Republic of the Congo; Disease Progression; Eflornithi | 2006 |
Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy.
Topics: Anaplasia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Disease Prog | 2007 |
Epidermal growth factor receptor expression in cervical intraepithelial neoplasia and its modulation during an alpha-difluoromethylornithine chemoprevention trial.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Biomarkers; Cervix Uteri; Disease Progression; Eflor | 1998 |
Difluoromethylornithine chemoprevention of epidermal carcinogenesis in K14-HPV16 transgenic mice.
Topics: Administration, Oral; Animals; Anticarcinogenic Agents; Carcinoma, Squamous Cell; Disease Progressio | 1999 |
Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials.
Topics: Antineoplastic Agents; Biopsy; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cell | 1999 |
Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells.
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cel | 2001 |
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Antigens, Polyomavirus Transforming; Apoptosis; Cell Division; Deh | 2001 |